Lord Clement-Jones – 2016 Parliamentary Question to the Department of Health
The below Parliamentary question was asked by Lord Clement-Jones on 2016-02-24.
To ask Her Majesty’s Government when they expect a reimbursement decision on each of the drugs launched since June 2015 that were affected by the pause in listing new drugs on the Cancer Drugs Fund list.
Lord Prior of Brampton
Since June 2015, the National Institute for Health and Care Excellence (NICE) has published final technology appraisal guidance on the cancer drugs/indications listed in the following table.
|
Topic title |
Final guidance publication |
|
Melanoma (unresectable, metastatic) – pembrolizumab (after ipilimumab) [TA357] |
October 2015 |
|
Melanoma (unresectable, metastatic, ipilimumab naive) – pembrolizumab [TA366] |
November 2015 |
|
Multiple myeloma – panobinostat (post 1 prior therapy) [TA380] |
January 2016 |
|
Melanoma (advanced, unresectable, metastatic) – nivolumab [TA384] |
February 2016 |
NHS England has advised that it envisages, under the new arrangements for the Cancer Drugs Fund (CDF), that a greater number of cancer drugs will be funded from baseline commissioning. Under the new process, any drugs that receive either a draft recommendation for routine commissioning or, where uncertainty exists, a recommendation for use within the CDF, will receive interim funding from the CDF from the point of marketing authorisation.
NICE has advised that it is unable to provide a forecast as to when this will occur for technology appraisals published during the first year of the new CDF as this will depend on a number of factors including the value proposition put forward by manufacturers.
